Workflow
互联网+健康
icon
Search documents
"校园公益医生"项目落地"易享健康·送健康进校园"公益行动升
Xin Hua Wang· 2025-12-29 10:42
Core Viewpoint - The launch of the "Campus Public Doctor" project marks a significant upgrade to the "Yishang Health: Bringing Health to Campus" public welfare initiative, which aims to enhance healthcare access for rural students through collaboration between Sinopec Easy Joy and Shengli Xiangjian [1][3] Group 1: Project Overview - The "Yishang Health: Bringing Health to Campus" initiative addresses urgent issues such as weak public health infrastructure and insufficient medical services in rural schools, aiming to protect the health of rural teachers and students [3][4] - The project has established a professional support system and a comprehensive public service network, providing health services to numerous rural schools across 13 provinces, connecting with over 30,000 teachers and students [4] Group 2: Professional Support and Services - A team of 16 senior physicians from top hospitals has been assembled to provide comprehensive medical support, covering various fields such as child development, chronic diseases, and psychological counseling [4] - The initiative includes health lectures and live broadcasts to educate students on essential health skills, making health knowledge practical and accessible [4] Group 3: Future Plans and Innovations - The project will implement a five-year plan that includes regular health check-ups and educational activities in schools, focusing on children's mental health and support for left-behind girls [5] - An innovative full-process service system will be established, integrating "screening, initial diagnosis, referral, accompaniment, and rehabilitation tracking" to enhance the efficiency and precision of health services [5][7] Group 4: Company Commitment and Achievements - Shengli Xiangjian, established in 2013, has provided quality health services to over one million employees and their families, reinforcing its commitment to social responsibility and rural health support [7] - The "Campus Public Doctor" project represents a new starting point for the company in deepening its public welfare efforts and contributing to rural educational revitalization [7]
以岭药业与乐药集团达成合作 共拓医药健康产业新篇章
Cai Jing Wang· 2025-11-06 04:00
Core Insights - Yiling Pharmaceutical and Leyao Group have signed a cooperation agreement to establish a long-term, stable, and comprehensive partnership aimed at promoting high-quality development in China's pharmaceutical and health industry [1][6]. Group 1: Company Profiles - Yiling Pharmaceutical is a leading enterprise in the Chinese traditional medicine sector, focusing on technological innovation and has developed over ten patented new drugs targeting major diseases such as cardiovascular diseases, respiratory infections, tumors, and diabetes [3]. - Leyao Group, with a registered capital of $256 million, operates as a new type of "pharmaceutical + internet" enterprise, focusing on pharmaceutical distribution and optimizing supply chain efficiency through e-commerce and logistics technology [3]. Group 2: Digital Transformation - Yiling Pharmaceutical is actively embracing digitalization, having established deep partnerships with several well-known e-commerce platforms to expand its "internet + health" service model [4]. - A significant collaboration with JD Health was initiated to launch a digital marketing project aimed at promoting core products like the Ba Zi Bu Shen capsule, providing comprehensive health management solutions for aging populations [4][5]. Group 3: Strategic Cooperation - The cooperation between Yiling Pharmaceutical and Leyao Group will leverage their respective strengths in branding, research, production, technology, marketing, and distribution to enhance core competitiveness and better serve patients and consumers [6]. - A regular high-level meeting mechanism and joint working groups will be established to ensure efficient progress and execution of strategic cooperation projects, focusing on key issues such as channel management and market coverage [7]. Group 4: Industry Impact - This strategic partnership is seen as a significant step for both companies and is expected to set a new benchmark for industry collaboration, injecting new momentum into the development of China's pharmaceutical and health industry [9].
以岭健康携手多方共建“健康战略联盟”,助力大健康产业高质量发展
Sou Hu Wang· 2025-08-29 04:50
Core Viewpoint - The 8th China Health Festival emphasizes the importance of managing health and integrates traditional Chinese medicine with modern technology to develop health products and services [1] Group 1: Event Overview - The event was held on August 28 in Shijiazhuang, organized by the China OTC Association and the Hebei Pharmaceutical Industry Association, with support from local government and Yiling Health Technology Co., Ltd [1] - The theme of the festival is "The Body Needs Management, Health Needs Governance" [1] Group 2: Strategic Collaborations - Yiling Health has formed strategic alliances with various parties to create a health strategic alliance focusing on resource integration, complementary advantages, and collaborative innovation [1] - A partnership with JD Health aims to develop an "Internet + Health" innovative service platform, enhancing consumer engagement and health service accessibility [3] - Collaboration with CITIC Bank explores a "Health + Finance" model, enhancing employee welfare and financial services through health product integration [5] Group 3: Innovative Health Services - Yiling Health is collaborating with multiple enterprises to enhance health services in various scenarios, including a partnership with Jiuyun Hengyuan to upgrade community health services through a nationwide property service network [7] - A joint initiative with Dajia Life Insurance aims to create a high-end service model combining insurance and health [7] - The company is also working with Tsinghua University to leverage digital tools for brand building and health knowledge dissemination, enhancing user engagement through diverse marketing strategies [7]
即时零售大战前传:互联网健康的十年“三国杀”
华尔街见闻· 2025-05-10 11:47
Core Viewpoint - The article discusses the evolution and competition among major Chinese internet platforms (Meituan, JD.com, and Alibaba) in the online healthcare and pharmaceutical retail sector over the past decade, highlighting their strategies, market dynamics, and the impact of the COVID-19 pandemic on their business models [1][5][8]. Group 1: Historical Development - In 2015, Meituan launched a "pharmaceutical" module in its food delivery app, marking its entry into the pharmaceutical sector [1]. - Around the same time, JD.com began building its self-operated pharmacy, expanding into the pharmaceutical retail space [2]. - The following year, Alibaba integrated its pharmaceutical business into Alibaba Health, signaling the start of the "Internet + Health" initiative [3]. - Initially, these companies expanded their product categories based on their existing business models, leading to unforeseen competition and convergence in the healthcare sector over the next decade [4][18]. Group 2: Impact of COVID-19 - The COVID-19 pandemic in early 2020 acted as a catalyst for rapid changes in the healthcare sector, increasing demand for health-related products and services [21]. - The pandemic heightened consumer demand for timely delivery of health products, prompting platforms to enhance their delivery efficiency [22]. - JD.com quickly expanded its "urgent medicine delivery" service, achieving significant coverage across cities and improving delivery times [24][27]. - Meituan established "Meituan Buy Medicine" as an independent business, signaling its serious commitment to the pharmaceutical retail market [29]. Group 3: Current Market Dynamics - By 2024, Meituan's O2O system had penetrated both urban and rural markets, with over 300 million cumulative users and partnerships with more than 250,000 retail pharmacies [54]. - JD Health adopted a multi-faceted approach with self-operated, B2C, and O2O models, reporting a revenue of 94 billion yuan from platform services in 2024, a nearly 20% increase [59]. - In contrast, Alibaba Health's revenue for the 2024 fiscal year was 270.42 billion yuan, significantly lower than JD Health, indicating a slower growth trajectory [61]. Group 4: Future Trends - The article suggests that the ongoing competition in the pharmaceutical retail sector is a precursor to broader trends in instant retail, with potential for further development in areas like medical testing and aesthetic medicine [79]. - Platforms are increasingly focusing on integrating online medical services with pharmaceutical sales, leveraging the growing demand for home testing and telemedicine [68][69]. - The future of internet health platforms will likely involve a blend of B2C and O2O models, catering to different consumer needs and preferences [66].